Novartis Pharmaceuticals Corporation: Gene Therapy Market Kite Pharma, Incorporated, Spark Therapeutics, Inc, GlaxoSmithKline, Adaptimmune, Bluebird bio, Celgene, Shanghai Sunway Biotech

Global Gene Therapy Market Expected to Reach USD 4,300 Million by 2021 says a study published by Polaris Market Research

The Global Gene Therapy market size is expected to reach USD 4,300 million market by 2021 according to a study published by Polaris Market Research.

Gene therapy is a novel method, which has the potential to treat, cure and even prevent disease by means of altering the gene expression, which in turn alters the protein in the body. Most of the diseases are caused by damaged; dysfunctional genes which when rectified can restore the normal function of the gene and give us the “long life”. Genetic disorders cause around 4000 diseases, which theoretically can be corrected by gene therapy, thus bringing the ray of hope especially for the terminally ill patients. The Rising demand of the personalized treatments and need for the one stop cure for the rare indications and niche segments of the disease has led to the emergence of the gene therapies as a therapy option for the critical and deadly indications. The positive attitude of regulatory bodies has also created a favorable environment for the research and development in these therapies.

Request For Sample Of This Research Report @ https://www.polarismarketresearch.com/industry-analysis/gene-therapy-market/request-for-free-sample

As of January 2018, there are 3000+ Reported Clinical Trials for Gene therapies, out of which 500+ trials are currently ongoing. The increase in the government funds for the research and development also paving the way for the secure future of gene therapies in coming time.

Polaris Market Research expects that with the expected launch of the potential gene therapies, the market is expected to rise at a higher pace. The Unites States accounts for the higher share of the market as compared to the Europe and Japan. The highest market size is subjected to the approval of KYMRIAH (Novartis), YESCARTA (Kite Pharmaceuticals) and LUXTURNA (Spark Therapeutics) and associated premium pricing.

Currently the Gene Therapy market is highly fragmented but with the current initiatives taken by the government and fastened approval process in developed countries, the market is soon going to be regulated.
The only restrain to the Gene Therapy market is premium pricing of the therapies. Polaris Market Research believes that the affordability of gene therapy is one of the primary concern in the mature markets.
GlaxoSmithKline recently in October 2017 launched the gene therapy, STRIMVELIS for the ultra-rare disorder i.e. Severe Combined Immunodeficiency due to Adenosine Deaminase deficiency (AD-SCID). This drug comes with the price tag of USD 665,000 which makes it the expensive drug in the entire gene therapy segment. The drug also comes with money back guarantee as reported by the company itself.

Browse Full Research Report with in-depth TOC @ https://www.polarismarketresearch.com/industry-analysis/gene-therapy-market/

The Leading Companies investigated in the gene therapy market Report includes-

Novartis Pharmaceuticals Corporation, Kite Pharma, Incorporated, Spark Therapeutics, Inc, GlaxoSmithKline, Adaptimmune, Bluebird bio, Celgene, Shanghai Sunway Biotech, Shenzhen SiBiono GeneTech, and SynerGene Therapeutics among Others

Polaris Market Research has provided the forecasts of the Global Gene Therapy Market from 2016-2021. The major segments which has been investigated in the global gene therapy market from 2016-2021 are:

1. Market Analysis by Marketed Gene Therapies
2. Market Analysis by Indications

The Marketed Therapies undertaken in forecast from 2016-2021 are:

1) Rexin-G (Epeius Biotechnologies Corporation)
2) Gendicine (SiBiono GeneTech Co., Ltd)
3) Neovasculgen [Human Stem Cells Institute (HSCI))
4) Glybera (UniQure Biopharma B.V.)
5) KYMRIAH (Novartis)
6) YESCARTA (Kite Pharmaceuticals)
7) LUXTURNA (Spark Therapeutics)
8) STRIMVELIS (GlaxoSmithKline)

The Major Indications in Gene Therapy are:

1) Cancer
2) Neurodegenerative Disorders
3) Lysosomal Storage Disorders (LSDs)
4) Ocular Diseases
5) Muscle Disorders
6) Anemia
7) Hemophilia
8) Severe Combined Immunodeficiency due to Adenosine Deaminase deficiency

Make an Inquiry for purchasing this report @ https://www.polarismarketresearch.com/industry-analysis/gene-therapy-market/inquire-before-buying

About Polaris Market Research

Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for our clientele spread across different enterprises. We at Polaris are obliged to serve our diverse customer base present across the industries of healthcare, technology, semi-conductors and chemicals among various other industries present around the world. We strive to provide our customers with updated information on innovative technologies, high growth markets, emerging business environments and latest business-centric applications, thereby helping them always to make informed decisions and leverage new opportunities. Adept with a highly competent, experienced and extremely qualified team of experts comprising SMEs, analysts and consultants, we at Polaris endeavor to deliver value-added business solutions to our customers.

Contact us

Mr. Neel
Corporate Sales, USA
Polaris Market Research
Phone: 1-646-568-9980
Email: neel@polarismarketresearch.com
Web: www.polarismarketresearch.com

This release was published on openPR.